This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Amikacin 500mg/2mL vial											
Amoxicillin/clavulanate 500mg/125mg tablet											
Bedaquiline 100mg tablet											
Clofazimine 50mg tablet/capsule											
Clofazimine 100mg tablet/capsule											
Cycloserine 250mg capsule											
Delamanid 50mg tablet											

**DR-TB:** Drug-Resistant TB EML: Essential Medicines List **EOI:** Expression of Interest

**ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Ethambutol 400mg tablet/capsule											
Ethionamide 250mg tablet/capsule											
Imipenem/cilastatin 500/500mg vial											
Isoniazid 300mg tablet/capsule											
Levofloxacin 250mg tablet/capsule											
Levofloxacin 500mg tablet/capsule											
Levofloxacin 750mg tablet/capsule											

**DR-TB:** Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest

**ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Linezolid 600mg tablet											
Meropenem 1000mg vial											
Moxifloxacin 400mg tablet/capsule											
PAS Sodium 4gm/5.52gm powder											
Pretomanid 200mg tablet											
Protionamide 250mg tablet/capsule											
Pyrazinamide 400mg tablet/capsule											

**DR-TB:** Drug-Resistant TB EML: Essential Medicines List **EOI:** Expression of Interest

**ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '22)	WHO Rapid Communication (DR-TB '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Pyrazinamide 500mg tablet/capsule												
Streptomycin 1000mg vial												_
Terizidone 250mg tablet/capsule												

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme









# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Ethambutol 400mg tablet/capsule											
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule											
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Isoniazid/Rifampicin 75/150mg tablet/capsule											
Moxifloxacin 100mg dispersible tablet											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status Yes No

N/A



# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Moxifloxacin 400mg tablet/capsule											
Pyrazinamide 400mg tablet/capsule											
Pyrazinamide 500mg tablet/capsule											
Rifabutin 150mg capsule											
Rifampicin 150mg capsule											
Rifampicin 300mg capsule											
Rifapentine 150mg tablet											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status Yes No

N/A



# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifapentine 300mg												
Rifapentine/Isoniazid 300mg/300mg tablet												
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet												
Rifapentine/Isoniazid/Moxifloxacin/ Pyrazinamide 300/75/100/375mg tablet												

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme









#### **Adult TB Preventive Treatment Dashboard**

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (TPT '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Isoniazid 300mg tablet/capsule											
Isoniazid/Rifampicin 75/150mg tablet/capsule											
Rifampicin 150mg capsule											
Rifampicin 300mg capsule											
Rifapentine 150mg tablet											
Rifapentine 300mg											
Rifapentine/Isoniazid 300mg/300mg tablet											

LTBI: Latent TB Infection TPT: TB Preventive Treatment EML: Essential Medicines List

**EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



#### **Adult TB Preventive Treatment Dashboard**

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (TPT '20)	WHO Guidelines (TPT '24)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 800/160/300/ 25mg tablet												

LTBI: Latent TB Infection

TPT: TB Preventive Treatment

EML: Essential Medicines List

**EOI:** Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Amoxicillin/clavulanate 500mg/125mg tablet											
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension											
Bedaquiline 20mg tablet											
Bedaquiline 100mg tablet											
Clofazimine 50mg tablet/capsule											
Cycloserine 125mg capsule											
Delamanid 25mg dispersible tablet											

DR-TB: Drug-Resistant TB EML: Essential Medicines List

EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Delamanid 50mg tablet											
Ethambutol 50mg dispersible tablet											
Ethambutol 100mg dispersible tablet											
Ethambutol 100mg tablet											
Ethionamide 125mg dispersible tablet											
Isoniazid 50mg dispersible tablet											
Isoniazid 100mg dispersible tablet											

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Levofloxacin 100mg dispersible tablet											
Linezolid 150mg dispersible tablet											
Linezolid 600mg tablet											
Meropenem 1000mg vial											
Moxifloxacin 100mg dispersible tablet											

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ E01 (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Moxifloxacin 400mg tablet/capsule												
PAS Sodium 4gm/5.52gm powder												
Pyrazinamide 150mg dispersible tablet												

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest

**ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme









## Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLcsubmitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	
Ethambutol 50mg dispersible tablet												
Ethambutol 100mg dispersible tablet												
Ethambutol 100mg tablet												
Ethionamide 125mg dispersible tablet												
Isoniazid 50mg dispersible tablet												
Isoniazid 100mg dispersible tablet												
Isoniazid 100mg tablet												-

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status Yes No

N/A



## Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	<b>EMLc</b> submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligit
Isoniazid 300mg tablet/capsule												
Pyrazinamide 150mg dispersible tablet												
Rifampicin 20mg/mL oral liquid												
Rifampicin/Isoniazid 75/50 dispersible tablet												
Rifampicin/Isoniazid/ Pyrazinamide 75/50/150mg dispersible tablet												

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024









#### Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLcsubmitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog
Isoniazid 50mg dispersible tablet											
Isoniazid 100mg dispersible tablet											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Levofloxacin 100mg dispersible tablet											
Rifampicin 20mg/mL oral liquid											
Rifampicin/Isoniazid 75/50 dispersible tablet											
Rifapentine 150mg dispersible tablet											

LTBI: Latent TB Infection EML: Essential Medicines List **EOI:** Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status Yes No

N/A



#### Pediatric TB Preventive Treatment Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (TPT '24)	WHO Guidelines (Children & Adolescent '22)	EMLcsubmitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifapentine 150mg tablet												
Rifapentine 300mg												
Rifapentine/Isoniazid 300mg/300mg tablet												
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 400/80/150/ 12.5mg tablet												

LTBI: Latent TB Infection **EML:** Essential Medicines List EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	EML	EMLc	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion Removed Rejected N/A
Linezolid injection 2mg/mL in 300mL bag								
Meropenem 500mg vial								
Meropenem/clavulanate 1000 mg/125 mg vial								
PAS 4gm granules								
PAS 500mg tablet								
PAS Injection								
PAS Sodium 4gm/9.2gm powder								
PAS Sodium 100gm powder								

EML: Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	EML	EMLC	WHO PQ EOI	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP recommended	GDF Catalog	Yes No Ineligible for inclusion Removed Rejected N/A
Streptomycin 750mg vial								
Terizidone 300mg tablet/capsule								
Terizidone 500mg tablet								

EML: Essential Medicines List EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024







Status

